During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Marek Trněný, Charles University General Hospital, Prague, CZ, about the impact of the total metabolic tumor volume on the identification of patients who failed treatment while refractory.
He also discusses two randomised trials that investigated lenalidomide and R-CHOP, mentioning that the phase III study failed to show benefits, while results of the phase II trial were positive.